Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company. The company's products focus on the therapeutic areas of central nervous system disorders, respiratory diseases, oncology, and other therapeutic areas. It operates across 57 markets and delivers medicines to more than 60 countries. Teva's business portfolio includes generic, biosimilar, innovative, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). It treats cardiovascular diseases, cancer, respiratory problems, diabetes, pain, and mental health issues. The company operates a distribution business and offers contract manufacturing services and an out-licensing platform through its affiliate Medis.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Teva focuses on the development of new medicines, devices, and combination products that offer significant therapeutic benefits to patients globally. The company's R&D initiatives focus on innovative biologics, biosimilars, small molecule medicines, generics, and over-the-counter therapies. Teva's R&D activities encompass preclinical assessment, clinical development, and regulatory strategy to ensure the successful registration of pipeline products. The company also emphasizes the development of high-value generics and complex formulations, leveraging its global R&D capabilities to address unmet patient needs in core therapeutic areas such as neuroscience, immunology, respiratory, and oncology. Teva’s R&D unit integrates scientific expertise across generic and specialty (branded) R&D capabilities, focusing on innovative medicines, generic medicines, biosimilars, and OTC medicines. The company operates development centers in the US, Europe, Latin America, Israel, Japan, and India. The company has more than 900 generic products in its pre-approved global pipeline, which includes products in all stages of the approval process. In FY2025, the company spent US$1,013 million on its R&D activities, which as a percentage of revenue, stood at 5.8% and grew by 1.5% YoY. As of December 2025, the company had 13 API production facilities, producing approximately 350 APIs in various therapeutic areas.